Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.35 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.34 |
| ▸ | USP2 | O75604 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869262 | 0.86 | PNP (0.34) | SARM1VSIRALDH1A1MAPTMEN1 | |
| SCHEMBL14869069 | 0.85 | CYP1A2 (0.43) | ALDH1A1MAPTMEN1KMT2ACYP2C19 | |
| SCHEMBL14869239 | 0.83 | LMNA (0.36) | ALDH1A1MAPTMEN1KMT2ACYP2C19 | |
| SCHEMBL14869269 | 0.77 | POLB (0.37) | ALDH1A1MAPTMEN1KMT2AHTT | |
| SCHEMBL14869223 | 0.76 | RAB9A (0.37) | SARM1VSIRALDH1A1MAPTMEN1 | |
| SCHEMBL14869017 | 0.75 | TAAR1 (0.48) | KDM4EPKM | |
| SCHEMBL16543314 | 0.74 | SARM1 (0.40) | SARM1VSIRALDH1A1MAPTMEN1 | |
| SCHEMBL14869163 | 0.73 | TAAR1 (0.39) | VSIRALDH1A1MEN1KMT2AHTT | |
| SCHEMBL14869080 | 0.72 | LMNA (0.48) | ALDH1A1MAPTMEN1KMT2AHTT | |
| SCHEMBL14869216 | 0.72 | MAOA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170202790-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2017-07-20 | — | — | US | disclosed |
| US-9480663-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150064223-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150064223-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064223-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | SARM1 2332/4885VSIR 4841/4885ALDH1A1 980/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | SARM1 2332/4885VSIR 4841/4885ALDH1A1 980/4885 |
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | SARM1 2547/4885VSIR 4840/4885ALDH1A1 1040/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | SARM1 2332/4885VSIR 4841/4885ALDH1A1 980/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | SARM1 2332/4885VSIR 4841/4885ALDH1A1 980/4885 |
| US-20170202790-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | SARM1 2332/4885VSIR 4841/4885ALDH1A1 980/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | SARM1 2332/4885VSIR 4841/4885ALDH1A1 980/4885 |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | SARM1 2332/4885VSIR 4841/4885ALDH1A1 980/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | SARM1 2547/4885VSIR 4840/4885ALDH1A1 1040/4885 |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | SARM1 2332/4885VSIR 4841/4885ALDH1A1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.